AstraZeneca Reports Strong Q3 Earnings, Stock Rises Over 2%

AstraZeneca, the British-Swedish multinational pharmaceutical company, announced its third-quarter earnings for the current year, posting a 4% increase in net profit to $1.43 billion, compared to $1.37 billion in the same period last year.

The financial report highlighted a 21% rise in total revenues, reaching $13.6 billion, with product sales totaling approximately $13 billion, up from $11 billion in the previous year's corresponding quarter. Given these solid results, AstraZeneca has raised its profit forecast for the fiscal year 2024.

In London Stock Exchange trading, AstraZeneca’s shares (LON: AZN) saw a 2.06% uptick, or £206 per share, bringing its price to £10,196.00.

Headquartered in Cambridge, England, AstraZeneca operates globally as a leader in the pharmaceutical and biopharmaceutical sectors, emphasizing its strong international footprint in this crucial industry.

Read also:

Corona - AstraZeneca developers accuse politicians of tarnishing the vaccine's reputation

The European Union reaches an agreement with AstraZeneca